TorreyPines Therapeutics has agreed to sell intellectual property and equipment assets to CalciMedica. The intellectual property includes a patent application describing assays and uses of STIM1 for regulating calcium-release activated calcium channels. CalciMedica also obtained several compounds, in the preclinical development stage, that inhibit CRAC channels and block the immune response. In exchange for the intellectual property, TorreyPines will receive CalciMedica common stock, as well as potential future sublicensing fees, milestone and royalty payments.
- see this release for more on the deal